Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke
Authors:
- Victorien MonguillonVMVictorien Monguillon
- Peter J. KellyPKPeter J. Kelly
- Michelle L. O’dOnoghueMOMichelle L. O’dOnoghue
- Jeong-Gun ParkJPJeong-Gun Park
- Erin A. BohulaEBErin A. Bohula
- Jeffrey L. SaverJSJeffrey L. Saver
- Dan AtarDADan Atar
- Anthony C. KeechAKAnthony C. Keech
- Peter S. SeverPSPeter S. Sever
- Gabriel Paiva da Silva LimaGLGabriel Paiva da Silva Lima
- Marc S. SabatineMSMarc S. Sabatine
Top Cited Papers
- 13 January 2026
- journal article
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (2) , 86-93
Abstract
BACKGROUND: Patients with previous ischemic stroke are at high risk for recurrent stroke and other major adverse cardiovascular events. The benefits of achieving very low levels of low-density lipoprotein cholesterol (LDL-C) in such patients is unclear. METHODS: We analyzed patients with previous ischemic stroke enrolled in FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), a randomized placebo-controlled trial studying evolocumab in patients with stable atherosclerotic cardiovascular disease (median follow-up, 2.2 years), and through the open-label extension (FOURIER-OLE) period (additional median follow-up, 5 years), to examine the relationship between achieved LDL-C and the long-term incidence of the primary end point (cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina or coronary revascularization) and stroke-related end points. RESULTS: The analysis included 5291 patients with previous ischemic stroke (>4 weeks). Of these, 666 (12.6%), 1410 (26.6%), 586 (11.1%), 508 (9.6%), and 2121 (40.1%) patients achieved LDL-C values of P trend P trend =0.85). CONCLUSIONS: In patients with previous ischemic stroke, it appeared that the lower the LDL-C, down to levels <40 mg/dL, the lower the risk of major adverse cardiovascular events, including recurrent stroke, without a clear increase in risk of hemorrhagic stroke. These findings support the concept that more intensive LDL-C lowering in patients with previous ischemic stroke may be warranted. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01764633/NCT01764633.Keywords
Funding Information
- Amgen (n/a)
This publication has 32 references indexed in Scilit:
- Long-Term Lipid Lowering With Evolocumab in Older IndividualsJACC, 2025
- Inhibition of PCSK9 Protects against Cerebral Ischemia‒Reperfusion Injury via Attenuating Microcirculatory DysfunctionNeurochemical Research, 2024
- LDL Cholesterol and Ischemic Stroke in Patients with Nonvalvular Atrial FibrillationThe American Journal of Medicine, 2021
- Alirocumab and Cardiovascular Outcomes after Acute Coronary SyndromeNew England Journal of Medicine, 2018
- Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trialThe Lancet, 2017
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseNew England Journal of Medicine, 2017
- Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trialAmerican Heart Journal, 2016
- The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trialsThe Lancet, 2012
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- High-Dose Atorvastatin after Stroke or Transient Ischemic AttackNew England Journal of Medicine, 2006